课题基金 / 基金详情

Rational Design of Antibiotics Targeted at the Ribosome

Rational Design of Antibiotics Targeted at the Ribosome
针对核糖体的抗生素的合理设计
批准号:
6833277
负责人:
Thomas C Hermann
金额:
$53.64万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-02-15 至 2006-08-31

项目摘要

项目成果

Thomas C Hermann的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Rapid and widespread emergence of antibiotics-resistant pathogens creates an urgent need for concerted approaches towards novel antiinfectives. The long-term objective of this proposal is the development of novel potent antibacterials that target the ribosomal RNA (rRNA) of antibiotics-resistant bacteria. Specifically, a lead series of small molecules that recognize the ribosomal decoding-site RNA (A-site) will be developed to select an antibacterial drug candidate by iterative rounds of synthesis and testing for target binding, inhibition of protein synthesis and bacterial growth. The ribosomal A-site constitutes a prime target for antibiotics, validated by the naturally occurring aminoglycosides and a novel series of chemically unrelated antibacterials that we have discovered recently. Rational structure-based design along with multi-dimensional drug optimization, using testing data from a range of biochemical and biological assays, will allow us to develop a novel class of antibiotics that are not susceptible to known bacterial resistance mechanisms. These novel antibacterial A-site ligands will constitute the first class of antibiotics that has been developed by a rational approach of drug discovery specifically directed at an RNA component of the bacterial ribosome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Broad-spectrum inhibitors targeting the viral replication promoter conserved in dengue and Zika viruses
Broad-spectrum inhibitors targeting the viral replication promoter conserved in dengue and Zika viruses
Chemotherapy targeting human thymidylate synthase messenger RNA
Chemotherapy targeting human thymidylate synthase messenger RNA
海外基金